Cargando…

Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease

Detalles Bibliográficos
Autores principales:	Chonat, Satheesh, Graciaa, Sara, Shin, H. Stella, Newton, Joanna G., Quarmyne, Maa-Ohui, Boudreaux, Jeanne, Tang, Amy, Zerra, Patricia E., Rollins, Margo R., Josephson, Cassandra D., Brown, Clark, Joiner, Clinton H., Fasano, Ross M., Stowell, Sean R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716365/ https://www.ncbi.nlm.nih.gov/pubmed/33256394 http://dx.doi.org/10.3324/haematol.2020.262006

Ejemplares similares

Eculizumab in chemotherapy-induced thrombotic microangiopathy
por: Schulte-Kemna, Lena, et al.
Publicado: (2020)

Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre
por: Grall, Maximilien, et al.
Publicado: (2021)

The use of eculizumab in gemcitabine induced thrombotic microangiopathy
por: Krishnappa, Vinod, et al.
Publicado: (2018)

The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
por: Gabr, Jihad Ben, et al.
Publicado: (2020)

Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children
por: Schoettler, Michelle, et al.
Publicado: (2022)

Decision-making about gene therapy in transfusion dependent thalassemia
por: Quarmyne, Maa-Ohui, et al.
Publicado: (2022)

Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab
por: Jin, Anna, et al.
Publicado: (2016)

Scleroderma Renal Crisis With Thrombotic Microangiopathy Treated With Eculizumab
por: Saba, Ludovic, et al.
Publicado: (2022)

Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy
por: Gomez-Ganda, Laura, et al.
Publicado: (2021)

Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding
por: Fujita, Yoko, et al.
Publicado: (2020)

Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab
por: Efe, Orhan, et al.
Publicado: (2021)

Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series
por: Vitkauskaitė, Monika, et al.
Publicado: (2022)

Bevacizumab-Associated Thrombotic Microangiopathy Treated with Eculizumab: A Case Report
por: Padilha, Wallace Stwart Carvalho, et al.
Publicado: (2023)

Gemcitabine-induced thrombotic microangiopathy treated with eculizumab: a case report
por: Van den Eeckhaut, Lisa, et al.
Publicado: (2022)

Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal
por: Thein, Swee Lay, et al.
Publicado: (2020)

Improving an Administrative Case Definition for Longitudinal Surveillance of Sickle Cell Disease
por: Snyder, Angela B., et al.
Publicado: (2019)

Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life‐saving treatment
por: Gosain, Rahul, et al.
Publicado: (2017)

The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report
por: Bjørkto, Magnus Holter, et al.
Publicado: (2021)

Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome
por: Raghunandan, Sharmila, et al.
Publicado: (2020)

Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome
por: Thomas, Christie P., et al.
Publicado: (2015)

Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab
por: Uriarte, Maite Hurtado, et al.
Publicado: (2018)

Treatment of Chemotherapy-Induced Thrombotic Microangiopathy with Eculizumab in a Patient with Metastatic Breast Cancer
por: Hausberg, Martin, et al.
Publicado: (2019)

A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy
por: Wright, Rachael D., et al.
Publicado: (2020)

Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma
por: Rassner, Michael, et al.
Publicado: (2021)

Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT
por: Mizuno, Kana, et al.
Publicado: (2022)

Correction to: T Cell‑Epstein‑Barr Virus–Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non‑Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH
por: Shamriz, Oded, et al.
Publicado: (2021)

T Cell-Epstein-Barr Virus–Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH
por: Shamriz, Oded, et al.
Publicado: (2021)

Assessment of Patient and Caregiver Attitudes and Approaches to Decision-Making Regarding Bone Marrow Transplant for Sickle Cell Disease: A Qualitative Study
por: Bakshi, Nitya, et al.
Publicado: (2020)

Patient and family experience with chronic transfusion therapy for sickle cell disease: A qualitative study
por: Hawkins, Lauren M., et al.
Publicado: (2020)

Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
por: Lanfranco, Luca, et al.
Publicado: (2017)

Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab
por: Allinovi, Marco, et al.
Publicado: (2017)

Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report
por: Facchini, Ludovica, et al.
Publicado: (2017)

Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy
por: Haninger-Vacariu, Natalja, et al.
Publicado: (2020)

Unique Presentation of Bortezomib-Associated Thrombotic Microangiopathy Responsive to Therapeutic Plasma Exchange and Eculizumab Therapy
por: Sterner, Robert C., et al.
Publicado: (2022)

Complement-Mediated Thrombotic Microangiopathy Associated with Lupus Nephritis Treated with Eculizumab: A Case Report
por: Torres, Everardo Arias, et al.
Publicado: (2021)

Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy
por: Sridharan, Meera, et al.
Publicado: (2022)

Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
por: Acosta-Medina, Aldo A., et al.
Publicado: (2022)

Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis
por: Zhang, Rui, et al.
Publicado: (2021)

Thrombotic Microangiopathy Secondary to Systemic Sclerosis with Severe Complement Activation Not Responsive to Eculizumab: A Case Report
por: Nakamura, Masahiko, et al.
Publicado: (2022)

Thrombotic Microangiopathies
por: Radhi, Mohamed, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_b5063r1n19o5m34crs84m8vajv